RET-fusion Non Small Cell Lung Cancer
2 clinical trials · Condition
◉ Watch RET-fusion Non Small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC (NCT04697446) | Blueprint Medicines Corporation | 2020-12-01 |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04222972) | Hoffmann-La Roche | 2020-07-24 |
Track RET-fusion Non Small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.